{
    "nctId": "NCT02762981",
    "briefTitle": "Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors",
    "officialTitle": "Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Tumors",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 85,
    "primaryOutcomeMeasure": "Number of Participants With Dose-limiting Toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with advanced or metastatic solid tumors who have disease progression after treatment with available therapies and for whom nab-paclitaxel treatment is appropriate.\n* Measurable or evaluable disease.\n* Up to 3 prior cytotoxic chemotherapeutics regimens or myelosuppressive therapies in the advanced setting.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* For Part 2 Only: Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, or Triple Negative Breast Cancer with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in at least 1 lesion, that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.\n\nExclusion Criteria:\n\n* Any major surgery within 4 weeks prior to the first dose of study drug.\n* Some protocol specified treatments prior to the first dose of study drug.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}